Artificial peptides for antitumoral siRNA delivery

Area of Science:

• Biomedical Engineering
• Nanomedicine
• Drug Delivery Systems

Background:

• Intracellular delivery is crucial for siRNA and related therapeutic nucleic acid efficacy.
• Advancements in delivery carriers are essential for future nanomedicine development.
• Current strategies require optimization for enhanced therapeutic outcomes.

Purpose of the Study:

• To optimize siRNA nanocarriers through a bioinspired, sequence-defined process.
• To evaluate the performance of artificial peptide evolution in tumor-directed siRNA delivery.
• To identify optimal nanocarrier properties for enhanced therapeutic efficacy.

Main Methods:

• Utilizing a bioinspired, sequence-defined process for nanocarrier optimization.
• Identifying artificial amino acids for specific delivery functions.
• Employing solid phase-assisted synthesis (SPS) for sequence assembly.
• Screening and selecting top siRNA delivery candidates based on structure-activity relationships.

Main Results:

• Medium-sized oligoaminoamides exhibit superior biological compatibility.
• Functionalized oligoaminoamides meet key siRNA delivery requirements.
• Nanocarriers demonstrate stable nanoparticle formation and bloodstream protein shielding.
• Effective tumor targeting and intracellular siRNA release in bioactive form were achieved.

Conclusions:

• The artificial peptide evolution strategy successfully optimized siRNA nanocarriers.
• Medium-sized oligoaminoamides represent a promising class of carriers for tumor-directed siRNA delivery.
• This approach enhances nanomedicine potential by improving delivery efficiency and biological compatibility.